Catalysts, not headlines
Biotech stocks do not trade on earnings the way other stocks do. A drugmaker can post no revenue at all and still double in a week, or fall by half on a single sentence from a data readout. The things that move these stocks are catalysts: scheduled events like trial data releases, regulatory decisions, and approval dates. If you want to know which biotech stocks to watch, you start by building a calendar, not a watchlist.
The “sub-$10 AI drug stock” promotion from Alexander Green’s Oxford Club is a useful case in point. The company behind it, Absci, is a microcap with a clinical-stage drug, and its near-term fate rests on a handful of dated events rather than on quarterly earnings. Understanding what those events are, and when they land, is the difference between watching a stock and understanding it.
The data readout is the big one
For a clinical-stage biotech, the single most important catalyst is the data readout: the moment the company announces whether its drug actually worked in patients. Absci’s lead asset, ABS-201, is an antibody for pattern hair loss, and its proof-of-concept data is expected in the second half of 2026, with fuller data in early 2027. That readout is binary. If the data is strong, the stock reprices around a real product; if it is weak, the platform story has to carry the valuation on its own.
This is why the timeline matters more than the narrative. The royalty-business story the promo tells is a long-term framing, but the catalyst that moves the stock in the next twelve months is a single data event. Our Absci stock piece walks through the price history and what is already priced in.
The rest of the calendar
Beyond the lead asset, Absci’s calendar includes a Phase 2 readout in endometriosis before year end and a hoped-for Phase 3 in hair loss as soon as late 2027. Each is a discrete event with the potential to move the stock, and each comes with its own risk of delay. Biotech timelines slip all the time, and a slipped timeline is its own catalyst, usually a negative one.
The same logic applies to the whole sector. A biotech stock to watch is not a company with a good story; it is a company with a dated event in the next twelve months. That event is the reason to pay attention now, and the reason the attention has an expiration date. Our AI healthcare stocks guide maps how these categories differ.
What a real catalyst looks like
A real catalyst is specific and dated. “Proof-of-concept data in the second half of 2026” is a catalyst. “The company is well positioned for the future” is not. The specific ones are the ones that move prices, because they are the points where uncertainty resolves. An investor holding through a catalyst is making a bet on the outcome, and the odds of that bet are what the current price is supposed to reflect.
The discipline for biotech is to know your catalyst, know your date, and know what you are willing to hold through. A stock with no near-term catalyst is a story you are paying to wait for; a stock with a dated catalyst is a trade with a defined resolution. Most promotional biotech pitches are the former dressed up as the latter. Our medical AI stocks explainer covers the software side of the sector, where the catalysts are approvals and adoption instead of data readouts.
The milestones after the data
Data is not the finish line. After a positive readout comes the regulatory filing, then the approval decision, then the commercial launch, and each of those is its own dated catalyst with its own risk. A drug can clear Phase 2 and still stumble on the manufacturing review or the pricing decision, which is why a single good readout rarely marks the top of a biotech’s run.
For a company like Absci, the sequence matters. The proof-of-concept data in the second half of 2026 is the first test, but a Phase 3 in hair loss as soon as late 2027 and an eventual approval are still ahead. Investors who only track the next data point miss the fact that biotech returns are a series of resolved bets, not one.
The watchlist, honestly
So which biotech stocks are actually worth watching? The honest answer is the ones with a catalyst you can name and a date you can put on a calendar. Absci qualifies, with proof-of-concept data due in the second half of 2026. The companies that do not qualify are the ones whose story is all forward-looking and whose calendar is empty, because a story without a date is a stock you can watch forever without ever learning anything.
Ready to see the research? Click here to access Alexander Green’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.